[A23-111] Midostaurin (systemic mastocytosis) – Benefit assessment according to §35a Social Code Book V
Last updated 15.03.2024
Project no.:
A23-111
Commission:
Commission awarded on 14.12.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Haematology
Adult patients with aggressive systemic mastocytosis, systemic mastocytosis with associated haematological neoplasm, or mast cell leukaemia
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A23-111_en
| Project no. | Title | Status |
|---|---|---|
| A23-110 | Midostaurin (acute myeloid leukaemia) – Benefit assessment according to §35a Social Code Book V | Commission completed |